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ackground: APOBEC3G (Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G) gene is 
one of the genetic host factors, have been linked with HIV-1 AIDS predisposing and protection in different 
residence populations. The investigation of genetic marker (APOBEC3G) variant (rs6001417) CC, CG 
and GG genotypes in Pakistan. 
Methods: The extraction of DNA, the DNA Rapid Salting-out method was used. Then the observed DNA with 
electrophoresis technique referred for quantitative real-time PCR to identify the APOBEC3G variant rs6001417 
genotypes and Taq Man genotyping.   
Results: Three genotypes of rs6001417 (CC, CG and GG) were compared both in HIV-1 infected patients and 
healthy control groups (p=0.73, p=0.007, p=0.01 respectively). The rs6001417 CG and GG genotype 
demonstrated a significant involvement in both the healthy and infected individuals and portraying possible 
protective effect against HIV-1 infection with predictive value of 36.43% and 13.57% respectively. 
Conclusion: APOBEC3G (rs6001417) CG and GG genotypes may have a protective feature in the progression 
of HIV-1 infection and we may use this as a preliminary predictive marker in the country for HIV-1 infected 
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Introduction  
HIV-1 infection is one of the global health problems, 
affecting almost 37.9 as million human population as of 
2019 according to UNAIDS worldwide, with 3.1 million 
new cases  reported every year [1-3, 40]. In recent past, 
HIV infection is highly prevalent in Sub-Saharan 
countries [4], however in Pakistan, currently it is one of 
the leading causes of morbidity and mortality as it hits 
approximately 160,000 infected individuals according to 
UN. Mostly HIV infection is being transmitted via 
contaminated blood and sexual contacts [5,6]. 
Immune related genetic mechanism can participate 
with the immune system while excluding a specific type 
of antigen from the body [7-11]. Recent findings portray 
that, both the host and viral genetics may have a 
substantial influence in the disease progression and 
protection [12-14]. In case of homozygous allelic variant 
of CCR5 protein has a substantial contribution in against 
the HIV infection [15,16]. Also, the ethnic background 
and DNA sequence similarity has a great role in the 
susceptibility and protection of a disease [17,19]. The 
only reason attracts  researchers globally to study the 
genetic role in the progression of HIV infection. 
In recent times, several studies have demonstrated 
that multiple host factors have influenced the 
pathogenesis of HIV-1/AIDS condition. These factors 
includes; APOBEC3G, Chemokine Receptor 5 (CCR-5), 
Dendritic Cell-Specific Intercellular adhesion molecule-3-
Grabbing Non-integrin (DC-SIGN), Tripartite motif 5a 
(TRIM5a), Tetherin, and (SAM-domain HD-domain 
containing protein) SAMHD1 [5,20-23]. These are 
antagonized by accessory viral proteins [24,25].  
Moreover, Apolipoprotein B mRNA editing enzyme 
catalytic polypeptide-like 3G (APOBEC3G) is an 
effective factor inside the host, which interferes with  HIV-
1 [22]. Virion infectivity factor (vif) which is structural part 
of  HIV-1 is able to counteract APOBEC3G antiviral 
activity by targeting it for degradation in proteasomes 
[26,27]. Vif proteins derived from subtypes A, B, 
CRF01_AE, and CRF_02AG  showed non-significant but 
some-what differential anti-APOBEC3G activity levels 
based on infectivity profiles while subtype C was highly 
significant [28,29]. The APOBEC3G protein was 
incorporated into newly synthesized viral particles, in the 
absence of the virion infectivity factor (vif), and 
deamination of cytosine (C) to uracil (U) made viral DNA 
mutated. APOBEC3G polymorphisms, such as (H186R) 
rs8177832, are supposed to be related with HIV-1 
subtype B and C pathogenesis in different ethnic groups 
[7,30], however this association is not  found in other 
populations [31-33]. These previous studies did not take 
the Circulating Recombinant Forms of HIV-1 into 
consideration, nor examine the effect of APOBEC3G 
polymorphisms in Asian Pakistani ethnic groups. The 
present study was  conducted to understand and make 
clear the role of rs6001417, variants of APOBEC3G in 
HIV-1 infection in Pakistani  population.     
Methods 
Study population 
A total of 240 subjects (100 patients and 140 healthy 
persons) were included in this study.  Samples were 
collected from different HIV centers of Pakistan and 
processed at Imperial Diagnostics and Research Center, 
Lahore. 
Sample collection, HIV-1 testing  
Intravenous blood  samples collected from HIV-1 
infected subjects were genotyped using Real Time PCR 
Quantitative kit (SYBR GreenER) 100-rxn  according to 
manufacturer’s instructions. 
DNA extraction and genotyping 
The DNA  was  extracted from blood  by using the “DNA 
Rapid Salting-out” procedure which has characterized by 
Miller et al [34].  The  extracted DNA  was stored at -20oC 
till  further processing. The  concept of SNP  was based 
on A3G variant rs6001417 along with the defense in 
contact with HIV-1  infection  [30]. The rs6001417 in 
regard to A3G  was genotyped by applying common 
SYBR GreenER SNP assay on the Fast Real-Time PCR 
Systems (Applied Biosystem Step One TM). PCR 
amplification was performed using the reverse and  
forward primers  respectively Table 1. Every reaction 
was consisted of absolute amount of 25 µl, containing 
10x PCR buffer 2.5 µl, Taq polymerase 0.5 µl, d-NTPs 1 
µl,  each primer 1 µl, genomic DNA 1 µl. The processing 
started by denaturation at 95℃, 30s of annealing at 55oC 
and 30s of extension  at 68℃, in 35 cycles. The final 
extension was, at 72℃ for 7 minutes. After 
electrophoresis over a 2 percent agarose gel with 0.5 
ug/ml ethidium bromide, the amplified product was  
examined on  UV light. 
Variant’s 
name 
Forward primer Reverse primer 
rs6001417                  
FP1 
CGCGTGCCACCATGAAGATC GTTACAGTCAGCGCCAGACCT 
Table 1: Primer of APO-BEC-3G variant rs6001417 
Ethical considerations 
The study  was approved from the  Institutional Ethical 
Committee of Imperial College of Business Studies and 
written consent from each participant was obtained. 
Statistical analysis 
The epidemiological data were recorded on a pre-
designed form and handled within excel software. All 
calculations were  performed by applying SPSS software 
version 20.0 statistical package. Data is expressed as 
Mean ± S.D and calibrations like diagnostic aspects has 
been calculated. Categorical variable was analyzed with 
X2 test. Hardy Weinberg equilibrium is also applied for 
Allele frequency. Contrasts to genotype placement of the 
groups were determined through the X2 trial. P<0.05 is 
considered as statistically significant. 
Results 
A total of 240 individuals were  included into the study. 
Study population consisted of 100 HIV-1 infected 
patients and 140 healthy controls. Gender wise 
distribution, age of the cases and healthy groups have 
been defined in Table 2. The mean age of the study 
population was 39.21±11.7 in the healthy control group 
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and 35.94±9.84 in the HIV-1 cases group. We found 
gender and age comparable variables among the two 
groups (P< 0.05). Genotype frequencies of the one 
APOBEC3G loci (rs6001417) for both the cases and 
controls  were given correspondingly in Table 2.  
1. Association between APOBEC3G variants and 
HIV-1 status 
We  analyzed and compared SNP rs6001417 genotypes 
( CC, CG and GG) between cases and control groups by 
using P-value of  > 0.05, as shown in Table 2. The 
electrophoresis pattern of APOBEC3G (rs6001417) CC, 
CG, and GG genotypes  was shown in Figure 1. 
 
Figure 1: Electrophoresis patterns for  genetic variations of APO-
BEC-3G rs6001417 CC,CG and GG genotypes.  
NOTE. Lane M, 184 bp marker; Lane 1, portraying homozygous CC 
genotype ; Lane 2, depicting heterozygous C/G genotype; Lane 3, 
providing information about homozygous GG genotype of APO-
BEC-3G  rs rs6001417. 




CC 70 (29.20%) 66 (27.50%) 136 (56.70%) 0.732 
CG 51 (21.20%) 27 (11.20%) 78 (32.50%) 0.007 
GG 19 (7.90%) 07 (2.90%) 26 (10.80%) 0.019 
HWE 3.55 2.93   






Table 2a: Association between APOBEC3G Polymorphism and 
HIV-1 status analysis. 
NOTE. HIV-1 individuals were considered as the dependent 
variable, whereas, APO-BEC-3G genotypes used as independent 
variables. Because APO-BEC-3G  rs6001417 CG  and GG genotype 
is significantly increasing than CC genotype in the control group, 
may be helpful in term of protection against HIV-1 status. 
1.1 APOBEC3G (rs6001417) 
The genotype frequencies of  APOBEC3G (rs6001417) 
CC, CG, and GG genotypes were 27.50%, 11.20%, 
2.90% in the patient with HIV-1 group and 29.20%, 
21.20%, 7.90% in the control group, respectively as 
shown in Table 1. Individuals account for HIV-1 infection 
has lower frequencies of the APOBEC3G (rs6001417) 
CG,GG genotypes than healthy individuals while CC   in 
HIV-1 patients. Chi-square analysis provided information 
that rs6001417 CG and GG genotypes (51 (21.20%) vs 
27 (11.20%) ; p=0.007 and 19 (7.90%) vs 07 (2.90%); 
p=0.019) reflect a significant variation between the two 
groups as shown in Figure 2. This analysis showed that 
subjects account for rs6001417 CG and GG genotype 
displays a protective role toward the HIV-1 infection. 
2. Association of gender with protective and 
predisposing attaining APOBEG3G variants 
genotypes  
We found rs6001417 CC,CG and GG genotype 
frequencies and distribution as 42.10%, 20.00%, 07.10% 
and 14.60%, 12.50%, 3.80%  in both male and female 
gender, respectively and had found comparable (P< 
0.05) Table 2, Figure 3. 
 
Figure 2: Association of protective rs6001417 CG and GG 
genotypes against HIV-1 status analysis. 
Note. Data is presented in percentages after analysed with  chi 
square analysis which predicted P-value among the male and 
female gender. 
Genotype Male Female % of 
Genotype 
P-value 
CC 42.10% 14.60% 56.70% <0.001 
CG 20.00% 12.50% 32.50% 0.062 
GG 07.10% 3.80% 10.80% 0.117 
% of Total 69.20% 30.80% 100% 0.138 
Table 2b: Association between APOBEC3G Polymorphism and its 
distribution in Genders. 
NOTE. This table illustrated the association of dependent variable 
(gender, i.e. male and female) with independent variable APO-
BEC-3G rs6001417 genotypes as rs6001417  CC genotype may 
link with gender Male which is being insignificant in both the HIV-
1 patients and control groups. 
 
Figure 3: Association of APHOBEG3G rs6001417 CC and CG 
protective genotypes and gender towards HIV-1 status analysis. 
NOTE. Frequency of genotypes were determined  by Pearson chi 
square test analysis, which also predict the significance level 
(<0.05) of genotypes among the two groups and data is shown in 
percentages. 
2.1 Analysis of gender with Protective (rs6001417) 
CG and GG genotypes 
The rs6001417 CG and GG genotype had a comparable 
association in both the male and female studied 
population (20.00% vs 12.50%; P= 0.062 and 07.10% vs 
3.80%; p=0.117) (Table 2). This analysis showed that, 
there is a comparable contribution of both male and 
female towards the protection in CG and GG individuals 
(reduces risk of being infected) of the HIV-1 studied 
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population. Moreover, (rs6001417) CC genotype  was 
more common in male than female in HIV-1 studied 
population and statistically significant (42.10% vs 
14.60%; p <0.001) as shown in Table 2. These findings 
showed the maximum contribution by male gender 
towards the CC genotype which is being insignificant in 
both the HIV-1 cases and control groups.  These 
comparisons were noticed in the HIV-1 studied 
population only. 
3. Predictive value of APOBEG3G (rs6001417) CG 
and GG genotypes  
We have already discussed  the protective rs6001417 
CG, and GG genotypes for HIV-1 infection. In addition, 
we examined predictive value of these two genotypes as 
well. Both the rs6001417 CG and GG genotypes were  
found to be the protective genotypes, we also  calculated 
positive predictive value (PPV) which was 36.43% and 
13.57%, respectively as shown in Table 3. 
APO-BEC-3G 
variants 
PPV NPV Specificity Sensitivity 
rs6001417  CG 36.43%  27.00% 23.28% 41.13% 
rs6001417  GG 13.57% 7.00% 5.47% 16.96% 
PPV (positive predictive value), NPV (negative predictive value). 
Table 3: Prediction of APO-BEC-3G  rs6001417 genotypes in HIV-
1 infection 
NOTE. According to this table, the protective rs6001417 CG and 
GG genotypes analyzed for positive and negative predictive value 
through Medcalc online calculator towards HIV-1 infection.  
Discussion 
Continual exposure to HIV infection does not certainly 
result in AIDS occurrence [35]. Multiple genetic and 
immune factors help in HIV acquirement, pathogenesis 
and AIDS progression at various stages of HIV life-cycle. 
So, HIV infection activates multiple intrinsic host factors 
that confer resistance to HIV pathogenesis, though the 
most important one is  intrinsic inhibition to HIV infection  
by APOBEC3G genetic host factor [24,36]. APOBEC3G 
single nucleotide polymorphisms (SNPs) are of particular 
importance and its twenty-nine SNPs have been studied 
in American [37] and European [38] cohorts to reveal its 
influence on AIDS development and progression. We 
examined the frequency distribution of the variants 
rs6001417 of APOBEC3G gene in the population of 
Pakistan. Moreover, we studied the APOBEC3G gene 
polymorphism without the fact of that virion infectivity 
factor (vif), as it degrades the HIV-1 virus along with 
APOBEC3G gene [26,27]. 
The most common genotype was CC of APOBEC3G 
variants (rs6001417) followed by CG, GG , in the whole 
studied population. Furthermore, it was observed, that 
APOBEC3G rs6001417 CG and GG genotypes provide 
significant protection with 36.43% and 13.57% positive 
predictive value (PPV) respectively, towards HIV-1 
infection. We have already reported predictive value in 
the treatment of HCV infection recently in which IL28B 
rs12979860 CT predicted 81.56% [39]. In a recently 
reported study from Pakistan, has shown that rs8177832 
AA genotype has a predisposing role whereas, 
rs8177832 AG genotype portrayed a protective 
prediction against HIV-1 disease [40]. Recently a study 
conducted in Burkina Faso revealed that APOBEC3G 
GGT haplotypes for rs6001417 variants have an 
influential outcome by providing protection against HIV 
infection in comparison to other haplotypes. The  results 
of the same study also demonstrated that individuals with 
haplotypes GGC  has an increase of two- to five-folds in 
susceptiblity against the HIV  infecton [41]. However, 
French cohort study showed a comparable association 
of APOBEC3G genetic variation, H186R, with the 
disease progression [31]. Interestingly, Tegwinde 
Rebeca Compaore et.al reported that rs6001417 GG 
and CG genotypes predicted protection and 
predisposing factor against the HIV-1 respectively, which 
is in line with our study that also showed both rs6001417 
GG and CG genotypes with protective feature [42].  
Moreover, in the recent past APOBEC3G was also 
studied with HBV infection, though a Moroccan based 
study where 179 chronic infected inviduals along with 
216 control were involved concluded with comparable 
results after testing hypothesis [43]. But, this variation of 
the results might be due to the distinct level of population 
and genetic makeup. This gentic variation was noted as 
higher as 37%, 3% and 5% in African Americans, 
Europian Americans and europian, respectively [7]. 
Similarly, Single Nucleotide polymorphisms of 
APOBEC3G docking proteins such as Vif and CUL5 can 
also help in the progression of the disease [44]. 
According to our studied population, the effect of 
APOBEC3G rs6001417 CC (42.10% vs 14.60% ; P = 
<0.001) genotype with in gender as it  found frequently    
in males compare to female. Therefore, the notion that 
the rs6001417 CT genotype may be supported by the 
male in term of protection or predisposing against HIV-1 
infection is not supported by our results because we 
found this CT genotype insignificant (neither protective 
nor predisposing). Interestingly,we reported gender 
association in recent past with IL28B rs12979860 CT 
genotype  against the spotaneous clearance of HCV 
infection, in which female gender supported CT 
genotype in term of spontaneous clearance of HCV 
infection [45].  To the best of our knowledge, no one has 
studied or reported the gender interaction with 
APOBEC3G gene polymorphism and HIV-1 infection. 
The limitations of this interaction, need further 
investigations as the sample size of our study was not 
enough and need further investigation in order to clarify 
the association. 
APOBEC3G polymorphisms variants (rs6001417) CG 
and GG genotypes may play a vital role at biological level 
in the interaction of HIV-1 susceptibility to the host, 
however, extra efforts are required on a larger cohort of 
patients to elucidate the association. 
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